MA44083A - Composés de biarylmonobactame pour le traitement d'infections bactériennes - Google Patents
Composés de biarylmonobactame pour le traitement d'infections bactériennesInfo
- Publication number
- MA44083A MA44083A MA044083A MA44083A MA44083A MA 44083 A MA44083 A MA 44083A MA 044083 A MA044083 A MA 044083A MA 44083 A MA44083 A MA 44083A MA 44083 A MA44083 A MA 44083A
- Authority
- MA
- Morocco
- Prior art keywords
- biarylmonobactam
- compounds
- treatment
- bacterial infections
- infections
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title 1
- 208000022362 bacterial infectious disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/16—Halogenated acetic acids
- C07C53/18—Halogenated acetic acids containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267855P | 2015-12-15 | 2015-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44083A true MA44083A (fr) | 2021-06-02 |
Family
ID=59057420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044083A MA44083A (fr) | 2015-12-15 | 2016-12-12 | Composés de biarylmonobactame pour le traitement d'infections bactériennes |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180339983A1 (fr) |
| EP (2) | EP3978472B1 (fr) |
| JP (1) | JP7184646B2 (fr) |
| KR (1) | KR20180093925A (fr) |
| CN (1) | CN108368040B (fr) |
| AU (1) | AU2016371600B2 (fr) |
| CA (1) | CA3008006C (fr) |
| MA (1) | MA44083A (fr) |
| MX (1) | MX2018005382A (fr) |
| RU (1) | RU2746129C2 (fr) |
| WO (1) | WO2017106064A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2768492C2 (ru) | 2011-11-18 | 2022-03-24 | Ридженерон Фармасьютикалз, Инк. | Полимерные белковые микрочастицы |
| ES2879826T3 (es) | 2015-06-15 | 2021-11-23 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| JP7184646B2 (ja) | 2015-12-15 | 2022-12-06 | メルク・シャープ・アンド・ドーム・エルエルシー | ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法 |
| BR112020006381A8 (pt) | 2017-10-02 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CN108362789B (zh) * | 2018-01-19 | 2020-09-01 | 珠海优润医药科技有限公司 | 一种阿维巴坦钠光学异构体的高效液相色谱检测方法 |
| JP7280273B2 (ja) * | 2018-01-29 | 2023-05-23 | メッドシャイン ディスカバリー インコーポレイテッド | 細菌感染を治療するための単環β－ラクタム化合物 |
| WO2020048828A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane |
| WO2020048827A1 (fr) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | Composés de la 1,3,9-triazaspiro[5.5]undécan-2-one |
| CN112771040B (zh) * | 2018-11-13 | 2022-10-18 | 南京圣和药业股份有限公司 | 单环内酰胺化合物及其应用 |
| WO2020113094A1 (fr) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Composés pyrrole et pyrazole et leurs procédés d'utilisation |
| CN111303144B (zh) * | 2019-12-13 | 2020-11-27 | 苏州信诺维医药科技有限公司 | 一种治疗细菌感染的化合物 |
| WO2021121387A1 (fr) * | 2019-12-19 | 2021-06-24 | 南京明德新药研发有限公司 | Application d'un composé dans la préparation de médicament |
| EP4007759A4 (fr) * | 2020-08-06 | 2024-04-10 | Ningxia Academy of Agriculture and Forestry Sciences | Composés de bêta-lactame, leur préparation et leur utilisation comme agents antibactériens |
| CN112661667B (zh) * | 2020-12-28 | 2023-02-03 | 浦拉司科技（上海）有限责任公司 | 一种三氟乙脒的制备方法 |
| CN113975396B (zh) * | 2021-11-09 | 2022-11-29 | 中国医学科学院医药生物技术研究所 | 包含β-内酰胺类化合物的药物组合物及其用途 |
| EP4433476A1 (fr) | 2021-11-18 | 2024-09-25 | Merck Sharp & Dohme LLC | Antibiotiques monobactams de chromane amidine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ203734A (en) * | 1982-03-31 | 1986-03-14 | Beecham Group Plc | Beta-lactam derivatives and pharmaceutical compositions |
| US4684722A (en) | 1986-01-06 | 1987-08-04 | E. R. Squibb & Sons, Inc. | Monosulfactams |
| CA2783572C (fr) * | 2005-12-07 | 2016-08-09 | Basilea Pharmaceutica Ag | Associations utiles d'antibiotiques monobactames et d'inhibiteurs de la beta-lactamase |
| AU2011336209B2 (en) | 2010-11-29 | 2015-03-19 | Pfizer Inc. | Monobactams |
| UY34585A (es) | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
| US8969570B2 (en) * | 2012-03-30 | 2015-03-03 | Cubist Pharmaceuticals, Inc. | Beta-lactamase inhibitors |
| US20140275007A1 (en) | 2013-03-14 | 2014-09-18 | Rempex Pharmaceuticals, Inc. | Oxamazin antibiotics |
| US20160326157A1 (en) | 2014-01-06 | 2016-11-10 | President And Fellows Of Harvard College | Monobactams and methods of their synthesis and use |
| PL3122745T3 (pl) * | 2014-03-24 | 2019-08-30 | Novartis Ag | Monobaktamowe związki organiczne do leczenia zakażeń bakteryjnych |
| JP7184646B2 (ja) | 2015-12-15 | 2022-12-06 | メルク・シャープ・アンド・ドーム・エルエルシー | ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法 |
-
2016
- 2016-12-12 JP JP2018530835A patent/JP7184646B2/ja active Active
- 2016-12-12 EP EP21204101.6A patent/EP3978472B1/fr active Active
- 2016-12-12 MX MX2018005382A patent/MX2018005382A/es unknown
- 2016-12-12 MA MA044083A patent/MA44083A/fr unknown
- 2016-12-12 US US15/775,487 patent/US20180339983A1/en not_active Abandoned
- 2016-12-12 CA CA3008006A patent/CA3008006C/fr active Active
- 2016-12-12 CN CN201680074091.0A patent/CN108368040B/zh active Active
- 2016-12-12 EP EP16876436.3A patent/EP3390357B1/fr active Active
- 2016-12-12 AU AU2016371600A patent/AU2016371600B2/en active Active
- 2016-12-12 KR KR1020187016482A patent/KR20180093925A/ko not_active Application Discontinuation
- 2016-12-12 WO PCT/US2016/066064 patent/WO2017106064A1/fr active Application Filing
- 2016-12-12 RU RU2018123484A patent/RU2746129C2/ru active
-
2020
- 2020-06-25 US US16/912,146 patent/US11230543B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018123484A3 (fr) | 2020-03-26 |
| EP3390357A1 (fr) | 2018-10-24 |
| JP2018537483A (ja) | 2018-12-20 |
| EP3390357A4 (fr) | 2019-06-12 |
| WO2017106064A1 (fr) | 2017-06-22 |
| RU2746129C2 (ru) | 2021-04-07 |
| US11230543B2 (en) | 2022-01-25 |
| CA3008006C (fr) | 2024-04-09 |
| KR20180093925A (ko) | 2018-08-22 |
| AU2016371600A1 (en) | 2018-05-10 |
| CN108368040B (zh) | 2024-08-23 |
| EP3390357B1 (fr) | 2021-11-10 |
| US20200361928A1 (en) | 2020-11-19 |
| RU2018123484A (ru) | 2020-01-17 |
| JP7184646B2 (ja) | 2022-12-06 |
| AU2016371600B2 (en) | 2021-02-18 |
| US20180339983A1 (en) | 2018-11-29 |
| EP3978472B1 (fr) | 2024-10-16 |
| EP3978472A1 (fr) | 2022-04-06 |
| CN108368040A (zh) | 2018-08-03 |
| CA3008006A1 (fr) | 2017-06-22 |
| BR112018010962A8 (pt) | 2023-04-11 |
| BR112018010962A2 (pt) | 2018-12-04 |
| MX2018005382A (es) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA45192A (fr) | Traitement d'association | |
| MA40867A (fr) | Méthodes pour le traitement d'infections virales à filoviridae | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA52371A (fr) | Méthodes de traitement d'infections dues aux coronaviridae | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA43811A (fr) | Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes | |
| MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
| MA41449A (fr) | Polythérapies pour le traitement de cancers | |
| MA50629A (fr) | Composés monobactames de chromane pour le traitement d'infections bactériennes | |
| MA54925A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| MA43000A (fr) | Polythérapie pour le traitement de tumeurs malignes | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| MA49576A (fr) | Compositions et méthodes pour le traitement d'infections fongiques | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA45552A (fr) | Compositions destinées au traitement de l'amylose | |
| MA45973A (fr) | Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple | |
| MA43570A (fr) | Thérapie génique pour traiter l'hypercholestérolémie familiale |